Key result
Low-dose aspirin did not significantly reduce overall dementia risk in type 2 diabetes (HR 0.82; 95% CI 0.58-1.16), but significantly reduced the risk in women (HR 0.58; 95% CI 0.36-0.95).
Why the study?
The study evaluated and compared the efficacy of long-term low-dose aspirin for dementia prevention in men versus women.
Does low-dose aspirin reduce the incidence of dementia in patients with type 2 diabetes?
RCT (n=2,536)
Open-label
Randomized
Does low-dose aspirin reduce the incidence of dementia in patients with type 2 diabetes?
Hazard Ratio: 0.82 (95% CI 0.58–1.16)
Long-term low-dose aspirin may reduce the risk of dementia in women with type 2 diabetes, though it shows no significant benefit in men or the overall population.
No takes yet. Share an insight, caveat, or question.
Should not yet change aspirin use for dementia prevention in type 2 diabetes; hypothesis-generating sex interaction requires randomized confirmation.
Matsumoto et al. (2019) conducted an RCT in Type 2 diabetes (n=2,536). Low-dose aspirin vs. Standard care was evaluated on Incidence of dementia (defined by the prescription of antidementia drugs or admission due to dementia) (HR 0.82, 95% CI 0.58-1.16). Low-dose aspirin did not significantly reduce overall dementia risk in type 2 diabetes (HR 0.82; 95% CI 0.58-1.16), but significantly reduced the risk in women (HR 0.58; 95% CI 0.36-0.95).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: